10x Genomics, Inc.

Equities

TXG

US88025U1097

Medical Equipment, Supplies & Distribution

Market Closed - Nasdaq Other stock markets 16:00:00 2024-05-17 EDT			5-day change	1st Jan Change
25.01 ^USD	-2.27%		-3.77%	-55.31%

05-15	Transcript : 10x Genomics, Inc. Presents at Bank of America Health Care Conference 2024, May-14-2024 04:20 PM
05-07	Bruker's NanoString Secures Patent Case Win in Germany	MT

10x Genomics, Inc. Reaffirms Revenue Guidance for the Year 2024

April 30, 2024 at 04:05 pm

10x Genomics, Inc. reaffirmed revenue guidance for the year 2024. The company maintaining its previously announced full year 2024 revenue guidance of $670 million to $690 million, representing 8% to 12% growth over full year 2023 revenue.

Latest news about 10x Genomics, Inc.

Transcript : 10x Genomics, Inc. Presents at Bank of America Health Care Conference 2024, May-14-2024 04:20 PM	05-14
Bruker's NanoString Secures Patent Case Win in Germany	05-07	MT
North American Morning Briefing : Stock Futures -2-	05-02	DJ
UBS Adjusts 10x Genomics Price Target to $30 From $52, Maintains Neutral Rating	05-01	MT
Earnings Flash (TXG) 10X GENOMICS Reports Q1 Revenue $141M, vs. Street Est of $142.1M	04-30	MT
Transcript : 10x Genomics, Inc., Q1 2024 Earnings Call, Apr 30, 2024	04-30
10x Genomics, Inc. Reaffirms Revenue Guidance for the Year 2024	04-30	CI
10x Genomics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	04-30	CI
Canaccord Genuity Adjusts Price Target on 10x Genomics to $50 From $65, Maintains Buy Rating	04-29	MT
Deutsche Bank Cuts Price Target on 10x Genomics to $55 From $60, Keeps Buy Rating	04-18	MT
10x Genomics, Inc. Commercially Launches Visium HD Spatial Gene Expression Assay	03-26	CI
10X Genomics Expands Xenium Menu with Multi-Modal Cell Segmentation Kit and Immuno-Oncology Gene Panel	03-21	CI
10x Genomics Launches Two New Products With Single Cell Technology	03-13	MT
10x Genomics, Inc. Begins Commercial Shipments of Chromium GEM-X Products	03-13	CI
Transcript : 10x Genomics, Inc. Presents at TD Cowen 44th Annual Health Care Conference 2024, Mar-05-2024 02:50 PM	03-05
UBS Adjusts 10x Genomics Price Target to $52 From $44, Maintains Neutral Rating	02-21	MT
Stifel Cuts Price Target on 10x Genomics to $63 From $68, Maintains Buy Rating	02-16	MT
10x Genomics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	02-15	CI
10x Genomics Q4 Net Loss Widens, Revenue Increases; Issues Outlook	02-15	MT
Earnings Flash (TXG) 10X GENOMICS Reports Q4 Revenue $184M, vs. Street Est of $183.7M	02-15	MT
Transcript : 10x Genomics, Inc., Q4 2023 Earnings Call, Feb 15, 2024	02-15
10x Genomics, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	02-15	CI
10X Genomics, Inc. Provides Revenue Guidance for the Full Year 2024	02-15	CI
10x Genomics, Inc. Expands Leadership in Single Cell Analysis with Launch of GEM-X Technology	02-07	CI
Transcript : 10x Genomics, Inc. Presents at 2024 AGBT General Meeting, Feb-07-2024 01:10 PM	02-07

Chart 10x Genomics, Inc.

Duration

Period

More charts

Company Profile

10x Genomics, Inc. is a life science technology company. The Company's integrated solutions include instruments, consumables and software for analyzing biological systems. Its Chromium platform includes its Chromium X Series, Chromium Connect and legacy Chromium Controller instruments, microfluidic chips and related consumables, which enables throughput analysis of individual biological components. Its Visium platform enables researchers to understand the spatial positions of biological analytes within tissues at high resolution. Its Xenium platform for in situ analysis is designed to give scientists the ability to not only locate and type cells in their tissue context. Its products include Chromium Single Cell Gene Expression, Chromium Single Cell Gene Expression Flex, Chromium Single Cell Immune Profiling, Chromium Single Cell assay for transposase accessible chromatin (ATAC), Chromium Single Cell Multiome ATAC + Gene Expression, Visium Spatial Gene Expression, and others.

Sector

Medical Equipment, Supplies & Distribution

Calendar

2024-06-11 - Annual General Meeting

More about the company

Income Statement Evolution

More financial data

Ratings for 10x Genomics, Inc.

Trading Rating

Investor Rating

ESG Refinitiv

D+

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

25.01 USD

Average target price

41.14 USD

Spread / Average Target

+64.51%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Diagnostic & Testing Substances

	1st Jan change	Capi.
10X GENOMICS, INC.	-55.31%	2.99B
BIOMÉRIEUX	-4.67%	12.32B
SHENZHEN NEW INDUSTRIES BIOMEDICAL ENGINEERING CO., LTD.	-5.19%	8.07B
DIASORIN S.P.A.	+9.45%	5.91B
LANTHEUS HOLDINGS, INC.	+28.50%	5.52B
AUTOBIO DIAGNOSTICS CO., LTD.	-8.09%	4.21B
ANDON HEALTH CO., LTD.	+13.49%	2.73B
VITROLIFE AB	-1.34%	2.43B
MYRIAD GENETICS, INC.	+32.24%	2.29B
GUANGZHOU WONDFO BIOTECH CO.,LTD	-3.55%	1.89B

Diagnostic & Testing Substances